Alzamend Neuro currently holds roughly 15.62
M in cash with (3.73
M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.18.
The firm shows a Beta (market volatility) of 0.6894, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Alzamend's beta means in this case. As returns on the market increase, Alzamend Neuro returns are expected to increase less than the market. However, during the bear market, the loss on holding Alzamend Neuro will be expected to be smaller as well. Even though it is essential to pay attention to
Alzamend Neuro historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's
future performance is to check both, its past performance charts as well as the business as a whole, including all available
technical indicators. Alzamend Neuro exposes twenty-one different technical indicators, which can help you to evaluate its performance.
Alzamend Neuro has an expected return of -0.0153%. Please be advised to confirm Alzamend Neuro
jensen alpha and
downside variance to decide if
Alzamend Neuro performance from the past will be repeated at some point in the near future.
Investing in Alzamend Neuro, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Alzamend Neuro along with other instruments in the same portfolio. Using conventional
technical analysis and
fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Please consider monitoring Alzamend Neuro on a daily basis if you are holding a position in it. Alzamend Neuro is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Alzamend Neuro stock to be traded above the $1 level to remain listed. If Alzamend Neuro stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Alzamend Neuro
financial leverage refers to using borrowed capital as a funding source to finance Alzamend Neuro ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Alzamend Neuro financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Alzamend Neuro's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Alzamend Neuro's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Alzamend Neuro's total debt and its cash.
Alzamend Neuro reported last year
Net Loss of
(9.95 Million). To perform a cash flow analysis of Alzamend Neuro, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Alzamend Neuro is receiving and how much cash it distributes out in a given period. The Alzamend Neuro cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Alzamend Neuro secures Sharpe Ratio (or Efficiency) of -0.002, which signifies that the company had -0.002% of return per unit of risk over the last 3 months. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and
technical indicators. Alzamend Neuro exposes twenty-one different
technical indicators, which can help you to evaluate volatility that cannot be
diversified away. Please be advised to confirm Alzamend Neuro
risk adjusted performance of
(0.012124), and Mean Deviation of 4.92 to double-check the risk estimate we provide.
Is Alzamend Neuro growth viable after the slide?
Latest kurtosis is at 7.38. Alzamend Neuro is displaying above-average volatility over the selected time horizon. Investors should scrutinize Alzamend Neuro independently to ensure intended market timing strategies are aligned with expectations about Alzamend Neuro volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Alzamend Neuro's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Alzamend Neuro's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Alzamend Neuro Implied Volatility
Alzamend Neuro's implied volatility exposes the market's sentiment of Alzamend Neuro stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Alzamend Neuro's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Alzamend Neuro stock will not fluctuate a lot when Alzamend Neuro's options are near their expiration.
Our Final Perspective on Alzamend Neuro
Whereas many other companies in the biotechnology industry are either recovering or due for a correction, Alzamend Neuro may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 13th of December 2021, we believe that at this point, Alzamend Neuro is very risky with
quite high odds of distress within the next 2 years. From a slightly different point of view, the entity appears to be
undervalued. Our primary 90 days buy-sell recommendation on the company is
Cautious Hold.
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Alzamend Neuro. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com